Lisata Therapeutics Announces Completion of Enrollment in the CENDIFOX Trial
December 10, 2024 08:30 ET
|
Lisata Therapeutics, Inc.
BASKING RIDGE, N.J., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment...
Lisata Therapeutics and Kuva Labs Announce Global License Agreement for Solid Tumor Imaging
December 03, 2024 08:30 ET
|
Lisata Therapeutics, Inc.
BASKING RIDGE, N.J. and HOUSTON, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”), a clinical-stage pharmaceutical company developing innovative therapies for...
Lisata Therapeutics Wins 2024 BioTech Breakthrough Award for ‘Specialized BioTherapeutics Company of the Year’
November 19, 2024 08:30 ET
|
Lisata Therapeutics, Inc.
Award recognizes Lisata’s data-driven approach and innovative therapies designed to address the unmet medical needs of patients with advanced solid tumors Annual BioTech Breakthrough Award is devoted...
Lisata Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
November 12, 2024 16:05 ET
|
Lisata Therapeutics, Inc.
Robust and expanding development portfolio with multiple key data readouts projected over the next 18 months Conference call scheduled for today at 4:30 p.m. Eastern Time BASKING RIDGE, N.J., Nov. ...
Lisata Therapeutics and Valo Therapeutics Announce Preclinical Research Collaboration
November 06, 2024 09:23 ET
|
Lisata Therapeutics, Inc.
BASKING RIDGE, N.J. and HELSINKI, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company developing innovative therapies for the...
Lisata Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update on Tuesday, November 12, 2024
November 06, 2024 08:30 ET
|
Lisata Therapeutics, Inc.
BASKING RIDGE, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced...
Lisata Therapeutics to Participate in Upcoming November 2024 Industry and Investor Events
October 31, 2024 08:30 ET
|
Lisata Therapeutics, Inc.
BASKING RIDGE, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced...
Lisata Therapeutics Announces Sponsored Preclinical Research Agreement with the University of Cincinnati to Study Certepetide for the Treatment of Endometriosis
October 28, 2024 08:30 ET
|
Lisata Therapeutics, Inc.
BASKING RIDGE, N.J., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced...
Lisata Therapeutics to Participate in Upcoming October 2024 Industry and Investor Events
October 03, 2024 08:00 ET
|
Lisata Therapeutics, Inc.
BASKING RIDGE, N.J., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies...
Lisata Therapeutics Announces First Patient Treated in the Second-line Cholangiocarcinoma Cohort of the BOLSTER Trial
September 17, 2024 08:00 ET
|
Lisata Therapeutics, Inc.
BASKING RIDGE, N.J., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies...